The U.S. administration has announced plans to support the distribution of lenacapavir, a groundbreaking HIV prevention drug developed by Gilead Sciences, through the PEPFAR program. This initiative aims to provide access to the drug for up to two million people in low- and lower-middle-income countries, particularly those with high rates of HIV. The partnership, which emphasizes affordable access, reflects a commitment to fighting the HIV epidemic, especially in marginalized communities. Health officials express optimism that this twice-yearly treatment could significantly impact HIV prevention efforts globally, as the U.S. plans to procure two million doses at cost to facilitate distribution in the most affected regions.